Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility
Northwest Biotherapeutics: Q3 Earnings Snapshot
Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed
Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.
Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
Northwest Biotherapeutics: Q2 Earnings Snapshot
Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments
Northwest Biotherapeutics: Q1 Earnings Snapshot
Northwest Biotherapeutics: A Spike On Their Expected Imminent Approval
Northwest Biotherapeutics: All Is Not Well With This One
Northwest Biotherapeutics Addresses Market Rumor Concerns
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property
Northwest Biotherapeutics announces exclusive license from Roswell Park
'$NWBO granted millions of stock options to insiders the day before DCVax paper published. But sure, keep banging on about naked shorts.'-STAT's Adam Feuerstein Tweets
Northwest Biotherapeutics Shares Quiet Following 13G Filing Disclosing 7% Stake by Capital Ventures
Northwest Biotherapeutics Prices ~4.895M Units at $4.80/Unit, Expecting Gross Proceeds $23.5M, Warrants for $6/Share
Northwest Biotherapeutics Files Prospectus Supplement for Stocks, Warrants
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.